Home/Kyverna Therapeutics/Keith Maher, JD

KM

Keith Maher, JD

Chief Business Officer

Kyverna Therapeutics

Therapeutic Areas

Autoimmune Diseases Immunology

Kyverna Therapeutics Pipeline

Drug	Indication	Phase
KYV-101	Lupus Nephritis (Systemic Lupus Erythematosus)	Phase 1/2
KYV-201	Undisclosed autoimmune indication	Preclinical

Leadership Team at Kyverna Therapeutics

Peter Maag, PhD

Chief Executive Officer

Dominik Rüttinger, MD, MSc

Chief Medical Officer

Jens Vogel, PhD

Chief Scientific Officer

Simona Skerjanec, PharmD, MBA

Chief Operating Officer

Timothy Lu, MD, MBA

Chief Financial Officer

Timothy Springer, PhD

Chair of the Board of Directors

Beth Seidenberg, MD

Luke Evnin, PhD

Cameron Durrant, MD, MBA

View full Kyverna Therapeutics profile